Skip to main content
| News

Boehringer Ingelheim acquires Basel’s NBE-Therapeutics

10.12.2020

German pharma group Boehringer Ingelheim is to acquire the Basel life sciences company NBE-Therapeutics for €1.18 billion. NBE-Therapeutics specializes in the development of cancer therapies.

NBE-Therapeutics is to become part of Boehringer Ingelheim. The Basel company is being acquired for €1.18 billion. It will remain at its campus at the Technology Park Basel and operate as a new site within Boehringer Ingelheim’s R&D network. ”This transaction is a validation of our platform and its potential for the next generation cancer therapies,” said Bertrand Damour, Chief Executive Officer of NBE-Therapeutics, in a press release.

The Basel biotech company is focused on antibody-drug conjugates (ADC) and advancing targeted cancer therapies derived from its immune stimulatory platform. The lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors.

Boehringer Ingelheim is gaining access to an innovative and unique platform that will decisively expand its cancer immunology portfolio. “We welcome NBE-Therapeutics’ richly talented team to Boehringer Ingelheim and we look forward to collaborating with them on this important work,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors.

Boehringer Ingelheim expects to close the transaction in the first quarter of 2021.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Sustainability

Evolva launches new line for manufacturers of personal care products

Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Record figure for startups in the Basel Area

Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...

Read More
Noema Pharma raises 103 million Swiss francs from investors
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Noema Pharma raises 103 million Swiss francs from investors

Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Why CDMO companies choose the Basel Area as their location

Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel still the most attractive small city for business in Europe

As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ariceum Therapeutics establishes subsidiary in Basel

The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...

Read More
1 2 3 61

Do you have a question? We'd like to hear from you.